Leland Stanford Junior University

Washington University

Vyera Pharmaceuticals, LLC

L David Sibley

Roland Buelow

James Walter Janetka

John Charles Boothroyd

Allen T Hopper

Jon Helander

The invention relates to inhibitors of calcium-dependent protein kinase 1 (CDPK1) and pharmaceutical preparations thereof. The invention further relates to methods of treatment of parasitic infections, such as, orinfections, using the novel inhibitors of the invention.

CDPK1 inhibitors, compositions, and methods related thereto

Diagnostic assays based on the discovery of dimorphism in the p30 antigen and gene and the direct association of this dimorphism with the known bimodal virulence pattern. Assays can be based on different antigenic behavior of virulent (referred to here as type I) and avirulent (type II) p30 antigens or on the differences in the corresponding genes. There is a one-to-one relationship between the type I and type II antigen/genes and virulence. Specific genetic materials, specific antibodies, and analytical techniques that allow a diagnosis to be made between virulent and avirulent infections are disclosed.

Composition and method for distinguishing virulent and non-virulent

Growing community of inventors

University City, MO, United States of America

L David Sibley